๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

A phase I trial of UCN-01 and prednisone in patients with refractory solid tumors and lymphomas

โœ Scribed by Shivaani Kummar; Martin E. Gutierrez; Erin R. Gardner; William D. Figg; Giovanni Melillo; Janet Dancey; Edward A. Sausville; Barbara A. Conley; Anthony J. Murgo; James H. Doroshow

Publisher
Springer
Year
2009
Tongue
English
Weight
181 KB
Volume
65
Category
Article
ISSN
0344-5704

No coin nor oath required. For personal study only.

๐Ÿ“œ SIMILAR VOLUMES

A Phase 1 study of UCN-01 in combination
A Phase 1 study of UCN-01 in combination with irinotecan in patients with resistant solid tumor malignancies
โœ Paula M. Fracasso; Kerry J. Williams; Ronald C. Chen; Joel Picus; Cynthia X. Ma; ๐Ÿ“‚ Article ๐Ÿ“… 2010 ๐Ÿ› Springer ๐ŸŒ English โš– 451 KB

## Purpose UCN-01 (7-hydroxystaurosporine) is a multi-targeted protein kinase inhibitor that exhibits synergistic activity with DNA-damaging agents in preclinical studies. We conducted a Phase I study to determine the maximum-tolerated dose (MTD), dose-limiting toxicity (DLT), pharmacokinetic, and

A phase I trial of ifosfamide and paclit
A phase I trial of ifosfamide and paclitaxel with granulocyte-colony stimulating factor in the treatment of patients with refractory solid tumors
โœ Craig A. Bunnell; Lynn Thompson; Lori Buswell; Ross Berkowitz; Michael Muto; Ell ๐Ÿ“‚ Article ๐Ÿ“… 1998 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 75 KB ๐Ÿ‘ 2 views

## Background: Ifosfamide and paclitaxel are antineoplastic agents with broad activity and with different mechanisms of action. a phase i trial was conducted to determine the maximum tolerated dose and associated toxicities of these agents when used in combination. ## Methods: Patients with refra